SCHEMBL700236

SCHEMBL700236

N#Cc1ccc(/C=C/c2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
MAPT P10636 2/20 0.59
LMNA P02545 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
TSHR P16473 1/20 0.59
FBP1 P09467 1/20 0.52
SNCA P37840 1/20 0.51
MAOB P27338 3/20 0.50
MAOA P21397 2/20 0.50
NR1H3 Q13133 1/20 0.50
NFE2L2 Q16236 1/20 0.50
CYP19A1 P11511 1/20 0.50
NPC1 O15118 2/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PKM P14618 1/20 0.47
KMT2A Q03164 1/20 0.47
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9803853 1.00 ALDH1A1 (0.59) ALDH1A1MAPTLMNAL3MBTL1TSHR
SCHEMBL11486259 1.00 ALDH1A1 (0.59) ALDH1A1MAPTLMNAL3MBTL1TSHR
SCHEMBL700237 1.00 ALDH1A1 (0.59) ALDH1A1MAPTLMNAL3MBTL1TSHR
Bromide SCHEMBL10654452 0.98 ALDH1A1 (0.58) ALDH1A1MAPTLMNAL3MBTL1TSHR
Bromide SCHEMBL10654444 0.98 ALDH1A1 (0.58) ALDH1A1MAPTLMNAL3MBTL1TSHR
(Z)-1,2-Diphenylethene SCHEMBL28593492 0.93 TSHR (0.70) ALDH1A1MAPTLMNAL3MBTL1TSHR
SCHEMBL1687899 0.92 NR1H3 (0.56) ALDH1A1MAPTLMNAL3MBTL1TSHR
SCHEMBL11329021 0.91 MAOB (0.61) ALDH1A1MAPTLMNAL3MBTL1TSHR
SCHEMBL11329024 0.91 MAOB (0.61) ALDH1A1MAPTLMNAL3MBTL1TSHR
SCHEMBL8699093 0.90 FBP1 (0.59) ALDH1A1MAPTLMNAL3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0358476-B1 Integrated optic components AKZO NOBEL NV (NL) 1998-07-22 EP claimed
US-5470692-A Integrated optic components AKZO NOBEL N.V. (NL) 1995-11-28 US claimed
US-5142605-A INTEGRATED OPTIC COMPONENTS BARR & STROUD LIMITED (GB) 1992-08-25 US claimed
EP-0358476-A2 Integrated optic components Akzo Nobel N.V. (NL) 1990-03-14 EP claimed
US-12404221-B2 Methods of arene alkenylation UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-09-02 US disclosed
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
WO-2022060378-A1 INTRAOCULAR LENS CARL ZEISS MEDITEC AG (DE) 2022-03-24 WO disclosed
EP-2909130-B1 CATALYSIS BY METAL NANOPARTICLES DISPERSED WITHIN A HIERARCHICALLY POROUS CARBON MATERIAL BAKKER MARTIN (US) 2022-01-26 EP disclosed
WO-2021074275-A1 EFFECTIVE PHOTOMODULATION OF LANTHANIDE (III) ION LUMINESCENCE IN THE VISIBLE OR NEAR-INFRARED RANGE UNIVERSITE DE RENNES 1 (FR) 2021-04-22 WO disclosed
US-9925153-B2 Therapeutic agents for skin diseases and conditions STC.UNM (US) 2018-03-27 US disclosed
US-4259482-A NON-SPECIFIC DEPRESSION OF CENTRAL NERVOUS SYSTEM MEAD JOHNSON & COMPANY (US) 1981-03-31 US disclosed
US-4217301-A Cyano-substituted stilbene compounds CIBA-GEIGY CORPORATION (US) 1980-08-12 US disclosed
US-4206142-A REACTING A STYRYLSULFONYLAMIDINE WITH A BASE MEAD JOHNSON & COMPANY (US) 1980-06-03 US disclosed
US-4130663-A ANTITHROMBOGENIC, ANTIHYPERTENSIVE MEAD JOHNSON & COMPANY (US) 1978-12-19 US disclosed
US-4097515-A Process for the manufacture of cyano-substituted stilbene compounds CIBA-GEIGY CORPORATION (US) 1978-06-27 US disclosed
US-4096183-A Styrylsulfonylamidines MEAD JOHNSON & COMPANY (US) 1978-06-20 US disclosed
US-4052455-A ANALGESICS, BLOOD PLATELET AGGREGATION INHIBITORS MEAD JOHNSON & COMPANY (US) 1977-10-04 US disclosed
US-4008224-A OPTICAL BRIGHTENER CIBA-GEIGY CORPORATION (US) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234900-A1 METHODS OF ARENE ALKENYLATION CYBB, CBR3, AHR ALDH1A1 414/4885MAPT 4342/4885LMNA 1425/4885
US-12404221-B2 Methods of arene alkenylation CYBB, CBR3, AHR ALDH1A1 414/4885MAPT 4342/4885LMNA 1425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.